Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-192.17%
operating margin TTM
-41.72%
revenue TTM
40.23 Million
revenue per share TTM
0.88$
valuation ratios | |
|---|---|
| pe ratio | -0.39 |
| peg ratio | 0.01 |
| price to book ratio | 0.72 |
| price to sales ratio | 1.05 |
| enterprise value multiple | -0.84 |
| price fair value | 0.72 |
profitability ratios | |
|---|---|
| gross profit margin | 50.82% |
| operating profit margin | -41.72% |
| pretax profit margin | -213.31% |
| net profit margin | -192.17% |
| return on assets | -101.28% |
| return on equity | -148.08% |
| return on capital employed | -27.35% |
liquidity ratio | |
|---|---|
| current ratio | 2.32 |
| quick ratio | 2.11 |
| cash ratio | 1.45 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 59.38 |
| operating cycle | 133.37 |
| days of payables outstanding | 135.80 |
| cash conversion cycle | -2.43 |
| receivables turnover | 4.93 |
| payables turnover | 2.69 |
| inventory turnover | 6.15 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.28 |
| debt equity ratio | 0.51 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.34 |
| interest coverage | -15.43 |
| cash flow to debt ratio | -0.60 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.29 |
| cash per share | 0.39 |
| operating cash flow per share | -0.23 |
| free cash flow operating cash flow ratio | 1.22 |
| cash flow coverage ratios | -0.60 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -4.62 |
Frequently Asked Questions
When was the last time ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) reported earnings?
ImmunoPrecise Antibodies Ltd. (IPA) published its most recent earnings results on 28-03-2025.
What is ImmunoPrecise Antibodies Ltd.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA)'s trailing twelve months ROE is -148.08%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. ImmunoPrecise Antibodies Ltd. (IPA) currently has a ROA of -101.28%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did IPA's net profit margin stand at?
IPA reported a profit margin of -192.17% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is IPA's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 2.32 in the most recent quarter. The quick ratio stood at 2.11, with a Debt/Eq ratio of 0.51.